Enzymatic generation of highly anticoagulant bovine intestinal heparin
dc.contributor.author | Fu, Li | |
dc.contributor.author | Li, Kevin | |
dc.contributor.author | Hirakane, Makoto | |
dc.contributor.author | Lin, Lei | |
dc.contributor.author | Grover, Navdeep | |
dc.contributor.author | Datta, Payel | |
dc.contributor.author | Yu, Yanlei | |
dc.contributor.author | Zhao, Jing | |
dc.contributor.author | Zhang, Fuming | |
dc.contributor.author | Mousa, Shaker A. | |
dc.contributor.author | Dordick, Jonathan S. | |
dc.contributor.author | Linhardt, Robert J. | |
dc.contributor.buuauthor | Yalçın, Murat | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Veteriner Fakültesi/Fizyoloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-5600-8162 | tr_TR |
dc.contributor.researcherid | AAG-6956-2021 | tr_TR |
dc.contributor.scopusid | 57192959734 | tr_TR |
dc.date.accessioned | 2022-11-03T12:10:59Z | |
dc.date.available | 2022-11-03T12:10:59Z | |
dc.date.issued | 2017-10-26 | |
dc.description.abstract | Unlike USP porcine heparin, bovine intestinal heparin (BIH) has a low anticoagulant activity. Treatment with 6-OST-1,-3, and/or 3-OST-1 afforded two remodeled heparins that met USP heparin activity and Mw specifications. We explored the pharmacodynamics and pharmacokinetics in a rabbit model. We conclude that a modest increase in the content of 3-O-sulfo groups in BIH increases the number of antithrombin III binding sites, making remodeled BIH behave similarly to pharmaceutical heparin. | en_US |
dc.description.sponsorship | United States Department of Health & Human Services National Institutes of Health (NIH) - USA - HL096972 - HL62244 - HL094463 - GM38060 | tr_TR |
dc.identifier.citation | Fu, L. vd. (2017). ''Enzymatic generation of highly anticoagulant bovine intestinal heparin''. Journal of Medicinal Chemistry, 60(20), 8673-8679. | en_US |
dc.identifier.endpage | 8679 | tr_TR |
dc.identifier.issn | 0022-2623 | |
dc.identifier.issn | 1520-4804 | |
dc.identifier.issue | 20 | tr_TR |
dc.identifier.pubmed | 28972371 | tr_TR |
dc.identifier.scopus | 2-s2.0-85032449266 | tr_TR |
dc.identifier.startpage | 8673 | tr_TR |
dc.identifier.uri | https://doi.org/10.1021/acs.jmedchem.7b01269 | |
dc.identifier.uri | https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01269?cookieSet=1 | |
dc.identifier.uri | http://hdl.handle.net/11452/29361 | |
dc.identifier.volume | 60 | tr_TR |
dc.identifier.wos | 000414114300030 | |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Amer Chemical | en_US |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.journal | Journal of Medicinal Chemistry | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Pharmacology & pharmacy | en_US |
dc.subject | Molecular-weight heparins | en_US |
dc.subject | Chemoenzymatic synthesis | en_US |
dc.subject | Induced thrombocytopenia | en_US |
dc.subject | Pharmaceutical heparins | en_US |
dc.subject | Chondroitin sulfate | en_US |
dc.subject | Porcine | en_US |
dc.subject | Binding | en_US |
dc.subject | Tissues | en_US |
dc.subject | Drugs | en_US |
dc.subject.emtree | 3 o sulfotransferase | en_US |
dc.subject.emtree | 6 o sulfotransferase | en_US |
dc.subject.emtree | Anticoagulant agent | en_US |
dc.subject.emtree | Antithrombin III | en_US |
dc.subject.emtree | Bovine intestinal heparin | en_US |
dc.subject.emtree | Heparin | en_US |
dc.subject.emtree | Sulfotransferase | en_US |
dc.subject.emtree | Unclassified drug | en_US |
dc.subject.emtree | Anticoagulant agent | en_US |
dc.subject.emtree | Enzyme | en_US |
dc.subject.emtree | Heparin | en_US |
dc.subject.emtree | Animal experiment | en_US |
dc.subject.emtree | Animal model | en_US |
dc.subject.emtree | Anticoagulation | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Binding affinity | en_US |
dc.subject.emtree | Binding site | en_US |
dc.subject.emtree | Bioengineering | en_US |
dc.subject.emtree | Chemical composition | en_US |
dc.subject.emtree | Enzyme modification | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Protein binding | en_US |
dc.subject.emtree | Animal | en_US |
dc.subject.emtree | Biosynthesis | en_US |
dc.subject.emtree | Bovine | en_US |
dc.subject.emtree | Carbohydrate analysis | en_US |
dc.subject.emtree | Chemistry | en_US |
dc.subject.emtree | Intestine | en_US |
dc.subject.emtree | Leporidae | en_US |
dc.subject.emtree | Metabolism | en_US |
dc.subject.emtree | Nuclear magnetic resonance spectroscopy | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Anticoagulants | en_US |
dc.subject.mesh | Carbohydrate sequence | en_US |
dc.subject.mesh | Cattle | en_US |
dc.subject.mesh | Enzymes | en_US |
dc.subject.mesh | Heparin | en_US |
dc.subject.mesh | Intestines | en_US |
dc.subject.mesh | Magnetic resonance spectroscopy | en_US |
dc.subject.mesh | Rabbits | en_US |
dc.subject.scopus | Heparan Sulfate; Heparosan; Glycosaminoglycans | en_US |
dc.subject.wos | Chemistry, medicinal | en_US |
dc.title | Enzymatic generation of highly anticoagulant bovine intestinal heparin | en_US |
dc.type | Article | |
dc.wos.quartile | Q1 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: